tradingkey.logo

GlucoTrack Inc

GCTK
6.080USD
-0.380-5.88%
Cierre 11/04, 16:00ETCotizaciones retrasadas 15 min
5.47MCap. mercado
PérdidaP/E TTM

Más Datos de GlucoTrack Inc Compañía

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

Información de GlucoTrack Inc

Símbolo de cotizaciónGCTK
Nombre de la empresaGlucoTrack Inc
Fecha de salida a bolsaApr 09, 2013
Director ejecutivoMr. Paul V. Goode, Ph.D.
Número de empleados11
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 09
Dirección301 Rt 17 North
CiudadRUTHERFORD
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal07070
Teléfono197286757878
Sitio Web
Símbolo de cotizaciónGCTK
Fecha de salida a bolsaApr 09, 2013
Director ejecutivoMr. Paul V. Goode, Ph.D.

Ejecutivos de GlucoTrack Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
2.65K
+94.49%
Dr. Victoria E. Carr-Brendel, Ph.D.
Dr. Victoria E. Carr-Brendel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Erin Carter
Ms. Erin Carter
Independent Director
Independent Director
--
--
Mr. Luis J. Malave
Mr. Luis J. Malave
Independent Director
Independent Director
--
--
Mr. Paul V. Goode, Ph.D.
Mr. Paul V. Goode, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter C. Wulff
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
2.65K
+94.49%
Dr. Victoria E. Carr-Brendel, Ph.D.
Dr. Victoria E. Carr-Brendel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Erin Carter
Ms. Erin Carter
Independent Director
Independent Director
--
--
Mr. Luis J. Malave
Mr. Luis J. Malave
Independent Director
Independent Director
--
--
Mr. Paul V. Goode, Ph.D.
Mr. Paul V. Goode, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter C. Wulff
Mr. Peter C. Wulff
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Ballantyne (John)
5.12%
John A Ballantyne Rev Trust
5.08%
BofA Global Research (US)
0.45%
Malave (Luis)
0.37%
Balo (Andrew K)
0.29%
Otro
88.68%
Accionistas
Accionistas
Proporción
Ballantyne (John)
5.12%
John A Ballantyne Rev Trust
5.08%
BofA Global Research (US)
0.45%
Malave (Luis)
0.37%
Balo (Andrew K)
0.29%
Otro
88.68%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
6.01%
Corporation
5.13%
Research Firm
0.46%
Hedge Fund
0.20%
Investment Advisor
0.10%
Investment Advisor/Hedge Fund
0.06%
Otro
88.05%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
28
7.28K
0.81%
+441.00
2025Q2
33
57.12K
10.07%
+7.03K
2025Q1
39
2.63M
26.00%
+2.61M
2024Q4
34
288.83K
2.77%
+184.21K
2024Q3
32
114.00K
32.14%
+19.53K
2024Q2
25
96.30K
35.98%
+32.90K
2024Q1
25
100.82K
37.68%
+41.48K
2023Q4
20
58.71K
36.83%
-16.43K
2023Q3
19
75.13K
44.69%
+1.11K
2023Q2
16
74.00K
44.15%
+21.12K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Ballantyne (John)
46.02K
5.12%
+45.95K
+66589.86%
Sep 23, 2025
John A Ballantyne Rev Trust
45.73K
5.08%
+1.00
+0.00%
Sep 23, 2025
BofA Global Research (US)
4.09K
0.45%
+4.09K
--
Jun 30, 2025
Malave (Luis)
2.86K
0.32%
-736.00
-20.48%
Sep 23, 2025
Balo (Andrew K)
1.36K
0.15%
-2.05K
-60.08%
Sep 23, 2025
Tower Research Capital LLC
1.77K
0.2%
+1.77K
--
Jun 30, 2025
Carter (Erin Catherine)
1.15K
0.13%
-613.00
-34.81%
Sep 23, 2025
Barclays Bank PLC
751.00
0.08%
+751.00
--
Jun 30, 2025
Sabby Management, LLC
539.00
0.06%
+539.00
--
Dec 31, 2024
Alma Diversified Holdings LLC
429.00
0.05%
--
--
Sep 05, 2024
Ver más

ETFs relacionados

Nombre
Proporción
Sin datos

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
Fecha
Tipo
Relación
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
Jan 30, 2025
Merger
20→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
May 15, 2024
Merger
5→1
KeyAI